What is Infermedica?
Infermedica specializes in AI-powered early symptom assessment, digital triage, and care navigation, providing healthcare organizations with essential tools for patient intake, symptom checking, and follow-up. Its Medical Guidance Platform, classified as a Class IIb Medical Device in the EU, adheres to stringent quality and data protection standards including ISO, HIPAA, GDPR, and SOC2. By integrating AI, LLMs, and NLP with a clinically validated Medical Knowledge and Inference Engine, Infermedica achieves 94% accuracy in its assessments. The platform supports over 20 languages and has facilitated more than 23 million health checks for over 100 organizations, including prominent names like Allianz Partners, Microsoft, and Teladoc Health. The company also offers Symptomate, a consumer-facing symptom checker.
How much funding has Infermedica raised?
Infermedica has raised a total of $40M across 2 funding rounds:
Series A
$10M
Series B
$30M
Series A (2020): $10M with participation from Karma Ventures, EBRD, Heal Capital, Inovo Venture Partners, and Dreamit Ventures
Series B (2022): $30M led by Heal Capital, Karma Ventures, Inovo, and European Bank for Reconstruction and Development
Key Investors in Infermedica
Karma Ventures
Karma Ventures is a European VC firm that invests in late seed and Series A deep-tech software startups, providing both funding and operational expertise to founders. The firm focuses on companies that create innovative technologies and have demonstrated initial commercial traction.
EBRD
The European Bank for Reconstruction and Development (EBRD) is a multilateral bank committed to the development of market-oriented economies and the promotion of the private and entrepreneurial initiatives.
Heal Capital
Heal Capital is a leading European HealthTech and AI venture capital firm with over EUR 200 million in assets under management and a portfolio of 27 companies. They specialize in investing between EUR 1-5 million in mission-driven HealthTech startups from Pre-Seed to Series A stages across Europe.
What's next for Infermedica?
The recent major strategic investment signifies Infermedica's transition into a scaling phase, likely enabling further expansion of its AI capabilities and market reach. This capital infusion is expected to fuel product development, enhance its Medical Guidance Platform, and solidify its partnerships with global healthcare providers. The company's focus on agentic AI and transparent data processing positions it for continued innovation in the digital health sector, aiming to improve patient outcomes and streamline healthcare navigation.
See full Infermedica company page
